Flu Vaccination in Patients with Cancer

Published: Thursday, Sep 25, 2008
Influenza epidemics occur every year in the United States, typically beginning in the late

fall or winter and concluding during the spring.1 During the 2006–2007 season, influenza

circulated at epidemic levels for about 14 weeks and peaked during February, the month

most frequently associated with peak activity over the past 31 influenza seasons.1,2 According

to estimates from the Centers for Disease Control and Prevention (CDC), influenza has

caused roughly 36,000 deaths and 226,000 hospitalizations annually.3,4 However, the rate

of flu varies each year based on viral virulence and duration of circulation. Complications,

hospitalizations, and death are most common in patients aged =65 years.5,6 In recent years,

there has been a growing recognition among oncologists and other cancer care professionals

of the importance of vaccination against influenza in patients with cancer.

For most people with cancer, vaccination for influenza is not only safe, but also a crucial part

of staying as healthy as possible. Owing to their weakened immune system, patients with cancer

are at high risk for infection with flu and pneumonia viruses, which can be lethal in these individuals.

Yearly flu and pneumonia shots often prevent infection entirely and can lessen the severity

of illness in those who do get sick.

Influenza Viruses

Influenza viruses are divided into three types, designated A, B, and C. Influenza types A and

B are responsible for epidemics of respiratory illness that occur almost every winter and are

often associated with increased rates for hospitalization

and death. Influenza type C differs from types A and B in some important ways.

Type C infection usually causes either a very mild respiratory illness or no symptoms at all;

it does not cause epidemics and does not have the severe public health impact that influenza

types A and B do. Efforts to control the impact of influenza are aimed at types A and B.

Influenza type A viruses are divided into subtypes based on differences in two viral proteins

called the hemagglutinin (H) and the neuraminidase (N). The current subtypes of influenza A

are designated A(H1N1) and A(H3N2). Influenza A(H1N1), A(H3N2), and influenza B strains are

included in each year’s influenza vaccine. In the years since its emergence, type A(H3N2) epidemics

have caused more than 400,000 deaths in the United States alone, and more than 90% of

these deaths have occur-red among people age 65 and older.

Influenza type A viruses undergo two kinds of changes. One is a series of mutations that

occur over time and cause a gradual change in the virus. This is called antigenic “drift.” This

constant changing enables the virus to evade the immune system of its host, so that people

are susceptible to influenza virus infection throughout life. This process works as follows:

A person infected with influenza virus develops antibody against that virus; as the virus

changes, the “older” antibody no longer recognizes the “newer” virus, and reinfection can occur.

The older antibody can, however, provide partial protection against re-infection.

The other kind of change is an abrupt change in the hemagglutinin and/or the neuraminidase

proteins. This is called antigenic “shift.” In this case, a new subtype of the virus suddenly

emerges. Type A viruses undergo both kinds of changes; influenza type B viruses change only

by the more gradual process of antigenic drift.

CDC Recommendations For Influenza Vaccination

Influenza vaccination is the most effective method for preventing influenza virus infection

and its complications, which may be severe The CDC updated its recommendations

regarding who should receive influenza vaccination in 2008.1,7 Current recommendations

regarding annual vaccination in children/adolescents and adults are summarized in Table 1

and Table 2, respectively. It is important to note that patients with cancer may fall into several

of the categories shown in the tables.

In 2008, the Advisory Committee on Immunization Practices (ACIP) of the CDC expandedits

recommendations for influenza vaccination for school-aged children.1,7 The ACIP-CDC

now recommends that all children aged six months to 18 years receive annual influenza

vaccination, beginning in 2008 if feasible, but beginning no later than during the 2009–2010

influenza season.1,7

Since influenza viruses undergo frequent antigenic change, persons recommended for

vaccination must receive an annual vaccination against the viruses known to be in circulation

each year.

According to the CDC,1 trivalent influenza vaccine may be used for any person aged

=6 months, including those with high-risk conditions. The 2008–2009 trivalent vaccine

virus strains are A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like,

and B/Florida/4/2006-like antigens.1 Live, attenuated-virus vaccine is currently approved

only for healthy, nonpregnant persons aged 5–49 years.

Flu Vaccination in Patients With Cancer

According to the CDC, less than 30% of patients with high-risk conditions, including cancer,

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication